Mapping the human genetic architecture of COVID-19
2021 · Nature · 1,104 citations
https://doi.org/10.1038/s41586-021-03767-x
C
Christoph D. Spinner
TUM Klinikum(DE)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
303
Papers
8.9K
Citations
37
h-index
118
i10-index
Christoph D. Spinner is an academic researcher from TUM Klinikum. The author has contributed to research in topics: COVID-19 Clinical Research Studies & SARS-CoV-2 and COVID-19 Research & HIV/AIDS Research and Interventions. The author has an h-index of 37, co-authored 258 publications.
ORCID: 0000-0002-3875-5367Papers by this author
worksClinical and virological features of first human monkeypox cases in Germany
2022 · Infection · 150 citations
https://doi.org/10.1007/s15010-022-01874-z
Clinical characteristics of monkeypox virus infections among men with and without <scp>HIV</scp>: A large outbreak cohort in Germany
2022 · HIV Medicine · 108 citations
https://doi.org/10.1111/hiv.13378
A second update on mapping the human genetic architecture of COVID-19
2023 · Nature · 107 citations
https://doi.org/10.1038/s41586-023-06355-3
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · The Lancet HIV · 88 citations
https://doi.org/10.1016/s2352-3018(21)00071-0
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · The Lancet HIV · 88 citations
https://doi.org/10.1016/s2352-3018(21)00071-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat